Health experts have long recommended engaging in physical activities, but many people do not exercise. Swiss food company Nestlé, however, appears to have found a solution to this dilemma with the “exercise in a bottle.”

The world’s largest food company said that research conducted by scientists from the Nestlé Institute of Health suggest that food and nutritional products may soon be able to provide some of the beneficial effects of exercise on the body’s metabolism and this could particularly benefit physically inactive individuals such as those with disability and disease as well as the elderly whose physical conditions prevent them from having an active lifestyle.

In the study “Mechanism of Action of Compound-13: An α1-Selective Small Molecule Activator of AMPK,” which was published in the Journal Chemistry & Biology on Nov. 24, Kei Sakamoto, from the Nestlé Institute of Health Sciences in Lausanne, Switzerland, and colleagues found that an enzyme that regulates metabolism and control how the body burns sugars and fats, can be controlled by a compound called C13.

In experiments involving mice, the compound C13 acts on the enzyme called AMP-activated protein kinase (AMPK) to stop the liver from producing fat.

“The enzyme can help people who can’t tolerate or continue rigorous exercise,” Sakamoto said. “Instead of 20 minutes of jogging or 40 minutes of cycling, it may help boost metabolism with moderate exercise like brisk walking.”

The researchers said that the findings of the study could possibly lead to the development of products that can help individuals suffering from metabolic disorder such as Type 2 diabetes and obesity as well as pave way to products that can augment the effects of exercise.

The development of such products can bring good news for those living a sedentary lifestyle. The researchers, however, cautioned that no product can replace exercise. Sakamoto said that given the number of effects that exercise offers, no single product can mimic all those effects.

Former President of America, Bill Clinton has called for the first AIDS-free generation by increasing the scale of HIV prevention and treatment across the globe. Clinton has said that the biggest issue for defeating AIDS would be early detection. Speaking about the issue, he said:

“New data from 51 countries suggests 70 percent of HIV-related deaths could have been prevented. The evidence continues to build that early treatment helps prevent further transmissions.”

The comment came at the 20th International AIDS Conference in Melbourne, Australia. Clinton also went on to note that:

“We are here on this 20th anniversary of the conference to celebrate so much of the progress that has been made because the world has made the right decision to fight against AIDS and to create a generation free of it.”

Currently, there are over thirty million people with HIV, across the globe, but less than a third of these people have access to treatment that has any chance of working – most notably antiretroviral treatment.

According to reports, approximately two million people are infected with HIV on a yearly basis; roughly 20,000 of these are infants and children.

Throughout Clinton’s speech, there was a protest calling for the implementation of a so called ‘Robin Hood’ tax.  This is a small tax on financial transactions such as trade in bonds, currency, shares and derivatives.

The protestors, who carried banners that read “End AIDS with Robin Hood Tax”, have cited economic experts that have said such a tax would not harm financial markets and would be simple to design and implement. One of the protestors said:

“The Robin Hood tax would finally ensure that the rhetoric on ending AIDS would become reality. People with HIV and communities at greatest risk of HIV infection around the world are waiting for life-saving treatments and services but global leaders are failing to act.”

It is now confirmed from the news that the mystifying respiratory virus pathogen that’s been affected children and caused them ill makes its way to the Northeast.

Officials announced the detail report on Friday that so many cases of enterovirus D68 have been registered in New York State and many hospitals have reported probable cases in the state.

The dangerous and mysterious pathogen that is responsible for dozens of children to hospitals in a Midwest normally attacks children with asthma in an initial stage and the Fox reported that the Department of Public Health, mentioned that there have been 97 affected cases of this virus given mid-August.

This virus affects on kids under 18 and earlier this week, a CDC dependable cases was found in 11 out of 14 samples from Chicago and 19 out of 22 samples from Kansas City, Missouri, in children age from 16 weeks to 16 years old and all the kids has a same medical history of asthma and breathless.

Dr. Howard Zucker, the Health Commissioner announced in a press release that there is no suggested vaccine, there is no cure, a best immunity is just to prevent it by practicing proper hygiene and as we all know it is important that we should take precaution and follow general clearness manners to prevent a widespread of this virus, as we take in for influenza and other foul illnesses.

Enteroviruses are associated with many symptoms that exemplify rashes and even neurological illnesses, but on the other hand, a CDC says in a report that if your child suffered from cold or flu, this illness will run a march in about a week so in this case parents should find medical assistance if cold symptoms start to connect wheezing or problem breathing.

The Physicians say that this virus can transmit by tightening hit with an affected person, or by touching objects or surfaces filled with a pathogen and afterwards touching a mouth, nose or eyes so they recommends holding easy perfect precautions, including washing hands regularly with soap and water, staying away from ill people, and disinfecting regularly overwhelmed surfaces.

Let’s talk about children first.  There are some beliefs that changing a mother’s diet during pregnancy or while breast feeding will prevent allergies.  Changing a child’s diet or formulas does not seem to prevent allergies.  Family genetics play a role here.

If there is a family history of eczema, food intolerances, and allergies, you can manage the situation in several different ways.  First, if the child is being breast fed continuing breast feeding until four months of age or more, this may help prevent cow milk allergy (atopic dermatitis) and the associated wheezing in early childhood. Make sure that you discuss infant feeding with your doctor.  You will want to follow their advise for introduction of new foods as your baby gets older.  Following the doctor’s recommendations may help prevent some allergies.

 

Another theory involving infant exposure to allergens is called the “hygiene hypothesis”.  It has been observed that infants that live on farms and are exposed to allergens, especially the airborne type, like animal dander and dust mites tend to have fewer allergies because their environment is not as clean as others.

As with any other allergies that have developed, following the prescribed treatment and avoiding the things that cause the allergies is the best method to prevent allergy attacks.

Keeping an ongoing list of allergies or what triggers them will help you a lot.  If you know what allergies, you have than you can try to avoid them. By avoiding things you know will trigger your allergies you’ll feel better.

Knowing the pollen pattern and when it is going to hit your area is one way to start treatment before the allergies hit you. You can get on the internet and search for allergies to find the sites that post all types of allergy and pollen information. Some will even send you e-mail and let you know 4 weeks before the allergy season is going to hit your town.

A new study revealed that people who wish to lose weight and improve their health should go for a low-carbohydrate diet. Low carbohydrate diet works better than the low fat diet since it also lessen the hazard of heart diseases.

However, a few researchers are still apprehensive about the impact of this diet on heart health because they are likely to be high in fat.

Dr. Lydia Bazzano, the main author of this study stated that people can lose more weight and decrease the risk factor of heart disease through appropriate nutritional counseling. In these nutritional counselling session nutritionist will notify them the benefits of the low-carbohydrate diet.

Moreover, Bazzano said that the outcome of this study demonstrates that if a person is overweight and have a cardiovascular disease risk element then a low carbohydrate diet would definitely help them.

Carbohydrates are found in food which contain sugar, fiber and starches. This sort of food is responsible to provide supply energy to the entire body.

The researchers presented the details of this study in the Annals of Internal Medicine. They wrote that these days low carb diets are more famous as compared to the other weight loss strategies. Nevertheless, the study showed mixed result regarding its cardiovascular risk factor.

The Experts performed this study with the help of 148 obese men and women between the ages of 22 and 75.  Researchers requested half of the people to adopt a low carbohydrate diet and assigned a low fat diet to the rest of the people. Participants were strictly asked not to abide by their routine physical activities.

All the members took a nutrition counseling session, The only difference was in the diets of the two groups.

The result of this experiment showed that the group who was on the low carbohydrate diet lost more weight and body fat.

Novartis has developed an experimental drug which is borne by several researchers since it demonstrated incredible results.

The trial treatment generally known as LCZ6696 slower down the hazards of cardiovascular deaths and admissions to health with a great number.

Milton Packer of University of Texas stated that it would be useless for doctors to prescribe the traditional medicines shortly after the availability of this drug. Moreover, he said that the outcome of this study is really amazing.

 

The researchers have failed to develop anything constructive in the arena of chronic heart disease. In this disease heart is unable to pump enough blood all around the body. Therefore, both the doctors and investors are quite enthusiastic about this medication.

This study also compared this drug to the older one which are usually urged by the doctors for this ailment. The researchers halted the study in the middle because the result of LCZ696 was really astonishing. However, the researchers revealed this news on Saturday at the annual meeting of the European Society of Cardiology (ESC). This conference is regarded as the world’s biggest cardiology congress.

ESC authorities marked the PARADIGM-HF experiment as the main discussion during the entire five day event.

Novartis is hopeful that this new drug will revitalize the wealth of the company. The data of this product is viewed as the most significant catalyst for the stock.

David Epstein, the company’s pharmaceutical head stated that the result of this drug is way better than what researchers have accepted.

The second most notable benefit of this drug is that it made patients feel evidently better.

Shedding the concerns over the stunted child’s growth due to the usage of stimulants for treating Attention Deficit Hyperactivity Disorder (ADHD), a new study has found that this type of medication has no adverse impact on the children’s final height in adulthood.

ADHD is the most common childhood neuro-developmental disorders that could often last into adulthood. It is commonly treated through a stimulant medication.

Between 70 and 80 percent of children with ADHD respond positively to stimulants, the Centers for Disease Control and Prevention (CDC) report said.


Five percent of children suffer from ADHD, the American Psychiatric Association said. However, these figures are said to be higher in the US. According to recent surveys of parents, it was found that around 11 percent of children between age group 4 and 17 years have been diagnosed with ADHD as of 2011. This makes the total affected from the disease to 6.4 million.

Children who suffer from this neurological disorder face difficulty in paying attention and controlling their impulsive behavior. They are found to be overly active.

According to the CDC, the risk factors or underlying causes that lead to the disorder are not known but genetic problems may play a significant role.
For studying the relation between stimulant medications and final adult height, the researchers involved 340 children with ADHD. All the participants were born between 1976 and 1982. The researchers compared the final height of the participating children when they turned adults with a control group of 680 children without the neurological disorder.

Following analysis of participants’ height and their stimulant treatment information during their adulthood, the researchers found that both ADHD and stimulant treatment were not linked with final height in adulthood.

“Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth,” the research group said.

The findings of the study were published in the American Academy of Pediatrics’ (AAP) journal Pediatrics.

Shedding the concerns over the stunted child’s growth due to the usage of stimulants for treating Attention Deficit Hyperactivity Disorder (ADHD), a new study has found that this type of medication has no adverse impact on the children’s final height in adulthood.

ADHD is the most common childhood neuro-developmental disorders that could often last into adulthood. It is commonly treated through a stimulant medication.

Between 70 and 80 percent of children with ADHD respond positively to stimulants, the Centers for Disease Control and Prevention (CDC) report said.


Five percent of children suffer from ADHD, the American Psychiatric Association said. However, these figures are said to be higher in the US. According to recent surveys of parents, it was found that around 11 percent of children between age group 4 and 17 years have been diagnosed with ADHD as of 2011. This makes the total affected from the disease to 6.4 million.

Children who suffer from this neurological disorder face difficulty in paying attention and controlling their impulsive behavior. They are found to be overly active.

According to the CDC, the risk factors or underlying causes that lead to the disorder are not known but genetic problems may play a significant role.
For studying the relation between stimulant medications and final adult height, the researchers involved 340 children with ADHD. All the participants were born between 1976 and 1982. The researchers compared the final height of the participating children when they turned adults with a control group of 680 children without the neurological disorder.

Following analysis of participants’ height and their stimulant treatment information during their adulthood, the researchers found that both ADHD and stimulant treatment were not linked with final height in adulthood.

“Our findings suggest that ADHD treatment with stimulant medication is not associated with differences in adult height or significant changes in growth,” the research group said.

The findings of the study were published in the American Academy of Pediatrics’ (AAP) journal Pediatrics.

The GlaxoSmithkline has fast-tracked an experimental Ebola vaccine. The firm intended to manufacture a stockpile of nearly 10,000 doses for emergency usage.

The experts struggled hard to develop a drug that can help to curb the worst outbreak of Ebola disease. The disease has almost killed 1,500 people in West Africa. An International group provided funds for the research work related to Ebola disease.

United National Institutes of Health (NIH) co-developed this vaccine with GSK.  Foremost, the experts will give this vaccine to healthy volunteer of Britain and United States from the month of September. Afterwards, the program will be stretched out to other countries such as the Gambia and Mali.

The GlaxoSmith said on Thursday that stage 1 experiment would begin soon after the approval of ethical and regulatory.

Currently, the NIH’s National Institute of Allergy and Infectious Disease is working on an extensive program of medical trials. These trials comprise of test of a GSK version which may help in struggling with the second type of Ebola.

Moreover, U.S researchers plan a human test of vaccine that is discovered by the scientist of  Canadian government.

Experts will uncover whether this vaccine is safe or trigger an  immune response through the healthy volunteers of experiment.

The chief goal of researchers is to accomplish this task till the end of year 2014.